Education plays an important role to help with understanding patient issues along with setting and aligning anticipations. a refined understanding of the pathogenesis of GO, will lead to newer more-effective treatments for the disease and improve patient quality of life. Keywords:Graves ophthalmopathy, thyroid eye disease, thyroid-associated ophthalmopathy == Introduction == Graves ophthalmopathy (GO) is the most common cause of orbital disease in adults and evolves in 25% to 50% of patients with Graves disease (GD).1Although thyroid manifestations of GD can be effectively managed, the prevention and ultimately treatment of GO has remained challenging. Most patients can be managed with nonsurgical treatment, which will be the focus of this article.2The surgical rehabilitation of GO has been reviewed Bis-PEG4-acid by others.3,4Here, we briefly review recent improvements in the understanding of GO pathogenesis as well as discuss current and future medical management strategies. == Disease pathogenesis == Depending on the diagnostic criteria utilized GO can be seen in 25% to 50% of patients with GD. The annual incidence of GO is usually approximately 16 in 100,000 women and 3 in 100,000 men.5The clinical course of GO differs from most autoimmune disorders in that there is typically an active phase with remission.6Symptoms and indicators of GO range from periorbital pain, conjunctival injection, chemosis, photophobia, diplopia, grittiness, lid lag and retraction, to proptosis, ophthalmoplegia, corneal ulceration, optic nerve dysfunction, and vision loss. Expansion of the orbital tissue (extraocular muscle tissue, connective tissue, and orbital excess fat) within the confines of the rigid bony orbit, can explain the majority of these observed findings. A complex interplay between genetic and environmental factors contributes to susceptibility to GD. Although genetic predisposition to GD is usually well established in the literature, the precise role of genetic factors in the development of GO is unknown.7Hereditary studies of GD have demonstrated a 30% to 40% concordance rate for monozygotic twins, while dizygotic twin studies reveal a lower Bis-PEG4-acid concordance rate of approximately 5%.8,9Non-twin siblings of patients with GD also have been noted to have an elevated risk when compared to the general population.8Numerous case-controlled studies examining the role of genetic factors in the development of both GD and GO have been performed. Multiple loci for GO have been proposed including human leucocyte antigen (HLA, 6p213), cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumor necrosis factor (TNF, 6p213), interferon-(12q14), intercellular adhesion molecule 1 (ICAM-1, 19p13), and thyroid stimulating hormone receptor gene (TSH-R, 14q31).7These results have not been confirmed or replicated in larger studies. It may be that both GD and GO are clinically heterogenous disorders making large-scale studies hard. The possibility that GO may be predominantly influenced by environmental factors, rather than genetic predisposition, remains.6 A unified theory to explain the pathogenesis of GO does not exist. GO is often (>90%), but not exclusively, associated with the onset of Graves hyperthyroidism, thus suggesting a common autoimmune pathogenic mechanism.10Once viewed as a bystander, orbital fibroblasts have been identified as a potential autoantibody target cell within the orbit. Thyroid-stimulating hormone receptors (TSHr) have been recognized in orbital fibroblasts of normal individuals and GO patients.1113At the mRNA level, patients with active GO have increased expression of TSHr versus patients with inactive disease.14Furthermore, orbital fibroblasts show increased TSHr expression after adipocytic differentiation.15Insulin-like growth factor-1 (IGF-1), another receptor around the orbital fibroblast cells, has also been shown to induce hyaluronan synthesis,16while thyroid-specific antigens such as thyroid peroxidase and thyroglobulin have been detected in orbital tissues.17,18Finally, autoantigens in extraocular Bis-PEG4-acid muscles (calsequestrin) and orbital fibroblasts (collagen XIII) were reported to be specific and sensitive diagnostic markers of GO.1921It should be noted that even though autoantibody theory of GO pathogenesis is speculative as the evidence is thus far insufficient to link it fully to the clinical manifestations of GO.22 Once activated, sub-populations Rabbit Polyclonal to KITH_HHV1 of orbital fibroblasts may release cytokines, produce glycosoaminoglycans (GAGs), and/or increase orbital fat through adipogenesis.23Interleukin-6 fibroblast secretion promotes B-cell development and differentiation, while other chemokines recruit (IL-16, CXCL10, and IL-16) and activate (IL-8 and CXCL10) T-cells.23Activated T cells trigger cytokine release (INF, TNF, PGD2, and 15-dPGJ2), thus potentiating further inflammation. 23One sub-population of activated orbital fibroblasts found predominantly in the orbital excess fat compartment termed preadipocytes, displays the ability to differentiate into mature adipocytes.24A individual orbital fibroblast sub-population found in connective tissues, that invests the extraocular muscles, may produce GAGs such as hyaluronic acid. Accumulation.